5-Chloro-2-(4-methylsulfanyl-phenyl)-3-phenethylamino-indolizine-1-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 5-Chloro-2-(4-methylsulfanyl-phenyl)-3-phenethylamino-indolizine-1-carbonitrile
• 英文别名: 5-Chloro-2-(4-(methylthio)phenyl)-3-(phenethylamino)indolizine-1-carbonitrile；5-chloro-2-(4-methylsulfanylphenyl)-3-(2-phenylethylamino)indolizine-1-carbonitrile
• 化学式: C₂₄H₂₀ClN₃S
• 分子量: 417.962
• InChiKey: AAPHFXLAXUBEAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯乙基乙腈 、 4-(甲基巯基)苯甲醛 、 6-氯-2-吡啶乙腈 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 正丁醇 为溶剂， 反应 16.0h， 以11%的产率得到5-Chloro-2-(4-methylsulfanyl-phenyl)-3-phenethylamino-indolizine-1-carbonitrile
  参考文献：
  名称：

  Discovery of protein–protein binding disruptors using multi-component condensations small molecules

  摘要：

  A series of small molecule compounds interfering with the binding process of VEGF and NRP1 has been identified and further optimized. Full synthetic details as well as SAR are reported which demonstrate that expeditious MCC-based syntheses may lead to valuable molecules addressing challenging targets such as protein-protein interactions. Preliminary functional assay data confirm that these compounds may be further developed toward drug candidates. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.014

文献信息

• Discovery of protein–protein binding disruptors using multi-component condensations small molecules
  作者：Karim Bedjeguelal、Hugues Bienaymé、Antoine Dumoulin、Stéphane Poigny、Philippe Schmitt、Eric Tam

  DOI：10.1016/j.bmcl.2006.05.014

  日期：2006.8

  A series of small molecule compounds interfering with the binding process of VEGF and NRP1 has been identified and further optimized. Full synthetic details as well as SAR are reported which demonstrate that expeditious MCC-based syntheses may lead to valuable molecules addressing challenging targets such as protein-protein interactions. Preliminary functional assay data confirm that these compounds may be further developed toward drug candidates. (c) 2006 Elsevier Ltd. All rights reserved.